

REMARKS

In response to the Restriction Requirement dated January 15, 2008, Applicant has elected Invention C, the protein of SEQ ID NO:21 or a nucleic acid encoding SEQ ID NO:21, for examination at this time. Claims 12-14, 16, 20-23, 26, 27, 30 and 31 read on the elected invention.

Applicant has amended claims 12, 16, 20 and 27 solely to remove recitation of non-elected subject matter. Applicant has canceled claims 19, 23 and 31 without prejudice. Support for all the above amendments may be found throughout the specification as originally filed. No new matter has been added. The present amendments are not to be construed as acquiescence with regard to the Examiner's rejections and are made without prejudice to prosecution of any subject matter removed or modified by this amendment in a related divisional, continuation or continuation-in-part application. Following the amendments, claims 12-14, 16, 20-22, 26-27 and 30 are pending and under consideration in the application.

Applicants respectfully submit that all of the claims remaining in the application are now believed to be in condition for allowance. Favorable consideration and a Notice of Allowance are earnestly solicited.

The Director is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment, to our Deposit Account No. 19-1090.

Respectfully submitted,

SEED Intellectual Property Law Group PLLC

/Julie A. Urvater/
Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

JAU:ms

701 Fifth Avenue, Suite 5400
Seattle, Washington 98104
Phone: (206) 622-4900
Fax: (206) 682-6031

1101390_1.DOC